N

Nykode Therapeutics ASA
OSE:NYKD

Watchlist Manager
Nykode Therapeutics ASA
OSE:NYKD
Watchlist
Price: 2.924 NOK 3.69% Market Closed
Market Cap: 954.8m NOK
Have any thoughts about
Nykode Therapeutics ASA?
Write Note

Wall Street
Price Targets

NYKD Price Targets Summary
Nykode Therapeutics ASA

Wall Street analysts forecast NYKD stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for NYKD is 13.464 NOK with a low forecast of 4.04 NOK and a high forecast of 26.25 NOK.

Lowest
Price Target
4.04 NOK
38% Upside
Average
Price Target
13.464 NOK
360% Upside
Highest
Price Target
26.25 NOK
798% Upside
Nykode Therapeutics ASA Competitors:
Price Targets
2162
KeyMed Biosciences Inc
118% Upside
MRNA
Moderna Inc
74% Upside
PAR
Paradigm Biopharmaceuticals Ltd
83% Upside
VRTX
Vertex Pharmaceuticals Inc
25% Upside
145020
Hugel Inc
44% Upside
206650
EuBiologics Co Ltd
30% Upside
VXRT
Vaxart Inc
509% Upside
GRAL
Grail Inc
8% Downside

Revenue
Forecast

Revenue Estimate
Nykode Therapeutics ASA

For the last 6 years the compound annual growth rate for Nykode Therapeutics ASA's revenue is 154%. The projected CAGR for the next 4 years is -6%.

154%
Past Growth
-6%
Estimated Growth
Estimates Accuracy
N/A
Average

Operating Income
Forecast

Operating Income Estimate
Nykode Therapeutics ASA

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
N/A
Average

Net Income
Forecast

Net Income Estimate
Nykode Therapeutics ASA

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
N/A
Average
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is NYKD's stock price target?
Price Target
13.464 NOK

According to Wall Street analysts, the average 1-year price target for NYKD is 13.464 NOK with a low forecast of 4.04 NOK and a high forecast of 26.25 NOK.

What is Nykode Therapeutics ASA's Revenue forecast?
Projected CAGR
-6%

For the last 6 years the compound annual growth rate for Nykode Therapeutics ASA's revenue is 154%. The projected CAGR for the next 4 years is -6%.

Back to Top